Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Stanford University
Mayo Clinic
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
M.D. Anderson Cancer Center
Essen Biotech
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
University Health Network, Toronto
University of California, Irvine
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Centre Hospitalier Universitaire Vaudois
M.D. Anderson Cancer Center
Vall d'Hebron Institute of Oncology
Essen Biotech
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Shanghai Zhongshan Hospital
BGI, China
University Health Network, Toronto
Instituto Oncológico Dr Rosell
Fred Hutchinson Cancer Center
UNICANCER
Sichuan University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Guangzhou Institute of Respiratory Disease
Mayo Clinic
Shenzhen Second People's Hospital
Washington University School of Medicine
Hoosier Cancer Research Network
Northwestern University
European Lung Cancer Working Party
University of Washington
Erasmus Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Fox Chase Cancer Center
Gundersen Lutheran Health System
Cancer Research UK
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Scripps Health